Entry Point Capital, LLC Xeris Biopharma Holdings, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
A detailed history of Entry Point Capital, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 34,633 shares of XERS stock, worth $118,791. This represents 0.06% of its overall portfolio holdings.
Number of Shares
34,633Holding current value
$118,791% of portfolio
0.06%Shares
2 transactions
Others Institutions Holding XERS
# of Institutions
143Shares Held
60MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$35.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$26.6 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$17.5 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$11.9 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$11.4 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $466M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...